 |
PDBsum entry 1hdl
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Putative serine proteinase inhibitor
|
PDB id
|
|
|
|
1hdl
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
328:205-219
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
Homologous proteins with different folds: the three-dimensional structures of domains 1 and 6 of the multiple Kazal-type inhibitor LEKTI.
|
|
T.Lauber,
A.Schulz,
K.Schweimer,
K.Adermann,
U.C.Marx.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
We have determined the solution structures of recombinant domain 1 and native
domain 6 of the multi-domain Kazal-type serine proteinase inhibitor LEKTI using
multi-dimensional NMR spectroscopy. While two of the 15 potential inhibitory
LEKTI domains contain three disulfide bonds typical of Kazal-type inhibitors,
the remaining 13 domains have only two of these disulfide bridges. Therefore,
they may represent a novel type of serine proteinase inhibitor. The first and
the sixth LEKTI domain, which have been isolated from human blood ultrafiltrate,
belong to this group. In spite of sharing the same disulfide pattern and a
sequence identity of about 35% from the first to the fourth cysteine, the two
proteins show different structures in this region. The three-dimensional
structure of domain 6 consists of two helices and a beta-hairpin structure, and
closely resembles the three-dimensional fold of classical Kazal-type serine
proteinase inhibitors including the inhibitory binding loop. Domain 6 has been
shown to be an efficient, but non-permanent serine proteinase inhibitor. The
backbone geometry of its canonical loop is not as well defined as the remaining
structural elements, providing a possible explanation for its non-permanent
inhibitory activity. We conclude that domain 6 belongs to a subfamily of
classical Kazal-type inhibitors, as the third disulfide bond and a third
beta-strand are missing. The three-dimensional structure of domain 1 shows three
helices and a beta-hairpin, but the central part of the structure differs
remarkably from that of domain 6. The sequence adopting hairpin structure in
domain 6 exhibits helical conformation in domain 1, and none of the residues
within the putative P3 to P3' stretch features backbone angles that resemble
those of the canonical loop of known proteinase inhibitors. No proteinase has
been found to be inhibited by domain 1. We conclude that domain 1 adopts a new
protein fold and is no canonical serine proteinase inhibitor.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. (a) and (c) Best-fit backbone superimposition of
the 21 lowest overall energy structures of domain 6 (a) and
domain1 (c) (generated with MOLMOL[63.]). Helical elements are
displayed in red, b-sheet structure is colored in green. (b) and
(d) Schematic drawing of a representative structure of domain 6
(b) and domain 1 (d), indicating regular secondary structural
elements (same color code as in (a) and (c)). The heavy
side-chain atoms of the P1 and P1' residues of domain 6 (Arg383
and Glu384) and the corresponding residues of domain 1 (Gln46
and Asp47) are shown (generated with MOLSCRIPT [65.] and
Raster3D [66. and 67.]).
|
 |
Figure 5.
Figure 5. Schematic drawings of the best-fit
superimpositions of matching structural elements of domain 6 and
BUSI IIA (2bus.PDB) (a) and of domains 1 and 6 (b). For BUSI IIA
and domain 1 helical elements are displayed in orange, b-sheet
structure is colored in cyan (for domain 6 same color code as in
Figure 3).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2003,
328,
205-219)
copyright 2003.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
P.Goettig,
V.Magdolen,
and
H.Brandstetter
(2010).
Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).
|
| |
Biochimie,
92,
1546-1567.
|
 |
|
|
|
|
 |
Z.Vasileiou,
K.K.Barlos,
D.Gatos,
K.Adermann,
C.Deraison,
and
K.Barlos
(2010).
Synthesis of the proteinase inhibitor LEKTI domain 6 by the fragment condensation method and regioselective disulfide bond formation.
|
| |
Biopolymers,
94,
339-349.
|
 |
|
|
|
|
 |
C.G.Roessler,
B.M.Hall,
W.J.Anderson,
W.M.Ingram,
S.A.Roberts,
W.R.Montfort,
and
M.H.Cordes
(2008).
Transitive homology-guided structural studies lead to discovery of Cro proteins with 40% sequence identity but different folds.
|
| |
Proc Natl Acad Sci U S A,
105,
2343-2348.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
C.Deraison,
C.Bonnart,
F.Lopez,
C.Besson,
R.Robinson,
A.Jayakumar,
F.Wagberg,
M.Brattsand,
J.P.Hachem,
G.Leonardsson,
and
A.Hovnanian
(2007).
LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction.
|
| |
Mol Biol Cell,
18,
3607-3619.
|
 |
|
|
|
|
 |
M.Tian,
and
S.Kamoun
(2005).
A two disulfide bridge Kazal domain from Phytophthora exhibits stable inhibitory activity against serine proteases of the subtilisin family.
|
| |
BMC Biochem,
6,
15.
|
 |
|
|
|
|
 |
N.M.Schechter,
E.J.Choi,
Z.M.Wang,
Y.Hanakawa,
J.R.Stanley,
Y.Kang,
G.L.Clayman,
and
A.Jayakumar
(2005).
Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).
|
| |
Biol Chem,
386,
1173-1184.
|
 |
|
|
|
|
 |
K.Adermann,
H.John,
L.Ständker,
and
W.G.Forssmann
(2004).
Exploiting natural peptide diversity: novel research tools and drug leads.
|
| |
Curr Opin Biotechnol,
15,
599-606.
|
 |
|
|
|
|
 |
T.Newlove,
J.H.Konieczka,
and
M.H.Cordes
(2004).
Secondary structure switching in Cro protein evolution.
|
| |
Structure,
12,
569-581.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |